Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

  • Track 1-1Neuronal Disorders
  • Track 1-2Neurotrauma
  • Track 1-3Peripheral Nervous System
  • Track 3-1Signal Transduction & CNS
  • Track 5-1Neuropathies
  • Track 5-2 Acoustic Neuroma
  • Track 5-3Neurosonology
  • Track 5-4Neuro-Oncology
  • Track 5-5Depression and Aging
  • Track 6-1Parkinson Diseases
  • Track 6-2Cerebral Hemodynamics
  • Track 6-3Multiple Sclerosis
  • Track 6-4Brain Stroke
  • Track 6-5Depression & Anxiety
  • Track 8-1Stress & Immune Function
  • Track 8-2Acute-Phase Reaction
  • Track 8-3Depression & Cognition
  • Track 8-4Stress Response
  • Track 8-5Research Methods in Psychoneuroimmunology
  • Track 8-6Psychological Treatments
  • Track 9-1Cerebrovascular Surgery
  • Track 9-2Advanced Operative Techniques in Neurosurgery
  • Track 9-3Traumatic Neurosurgery
  • Track 9-4Spine-Neurosurgery
  • Track 9-5Neurosurgical Care
  • Track 9-6Brain Neurosurgery
  • Track 10-1Brain Stimulation
  • Track 10-2Neuroinformatics
  • Track 10-3Neuroanatomy
  • Track 10-4Neurogenesis
  • Track 10-5Child Neurology
  • Track 10-6Neuroplasticity
  • Track 10-7Neurophysiology
  • Track 12-1Vaccines Research on Neurodisorder
  • Track 12-2vaccines on Neurological Damage
  • Track 12-3Vaccines and Brain Damage
  • Track 12-4Vaccine Induced Effects
  • Track 15-1Neurobiology of Disease
  • Track 15-2Stroke & Vascular Neurology
  • Track 15-3Systemic Disorders
  • Track 15-4Neurobiology Disease
  • Track 15-5Neuroepidemiology
  • Track 15-6Neurobiology Disease
  • Track 16-1Neurochemical Interactions
  • Track 16-2Molecular Neuropharmacology
  • Track 16-3Behavioral Neuropharmacology
  • Track 16-4Neuropsychopharmacology
  • Track 16-5Neuropharmacological Effects
  • Track 16-6Inflammation Pharmacology
  • Track 17-1Mental Health
  • Track 17-2Addictive Disorders
  • Track 17-3Neurotoxicity
  • Track 17-4Myasthenia Gravis & Related Disorders
  • Track 17-5Neurocognitive Changes in AIDS
  • Track 17-6Neurogenetic and Neurometabolic disorders
  • Track 19-1Neuroaesthetics & Critical Care
  • Track 19-2Neuroendoscopy
  • Track 19-3Neuro Imaging
  • Track 19-4Neuro Treatment & Device-Based Therapies
  • Track 19-5Cognitive Therapy Treatment
  • Track 19-6Medications
  • Track 19-7Testing and Diagnostics
  • Track 19-8Advance inTreatment
  • Track 20-1Neuro-Ophthalmology
  • Track 20-2Brain mapping
  • Track 20-3Immunostaining
  • Track 20-4Neuroepidemiology
  • Track 20-5Neuroethology
  • Track 21-1Practice Management & Reimbursement
  • Track 21-2Neurodevelopmental Disorder
  • Track 21-3Molecular Neuro Development Error
  • Track 21-4Developmental Neurobiology
  • Track 21-5Childhood Anxiety
  • Track 21-6Bipolar Disorder in Children
  • Track 22-1Diagnostic Tests
  • Track 22-2Complementary and Alternative Therapies
  • Track 22-3Surgery and Rehabilitation
  • Track 22-4Drug Therapy
  • Track 22-5Neuroimaging & Radiology
  • Track 22-6Occupational Therapy
  • Track 22-7Mindfullness Based Therapy
  • Track 22-8Brain Stem Cell Therapy